Immuneering Quick Ratio (IMRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immuneering Corporation  (NASDAQ: IMRX)

Immuneering's Quick Ratio

IMRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.14 below Immuneering Corporation average.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Immuneering in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 307 to 695.

Explain Quick Ratio?
How much Cash & cash equivalents IMRX´s has?
What are IMRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 13.99 % -4.08 % 40.59 % 38.94 % 10.05 %
Y / Y Cash & cash equivalent Change 58.34 % 31.94 % 255.92 % 349.22 % -55.87 %
Quick Ratio MRQ 5.14 10.37 12.77 24.83 3.7
IMRX's Total Ranking # 695 # 307 # 243 # 88 # 629
Seq. Current Liabilities Change 77.92 % -54.72 % 9.93 % 28.7 % 49.71 %
Seq. Cash & cash equivalent Change -11.81 % -63.22 % -43.47 % 763.44 % -26.52 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 186
Healthcare Sector # 297
Overall Market # 695


Quick Ratio Statistics
High Average Low
40.42 16.36 3.7
(Mar 31 2022)   (Jun 30 2025)




Financial Statements
Immuneering's Current Liabilities $ 8 Millions Visit IMRX's Balance sheet
Immuneering's Cash & cash equivalent $ 42 Millions Visit IMRX's Balance sheet
Source of IMRX's Sales Visit IMRX's Sales by Geography


Cumulative Immuneering's Quick Ratio

IMRX's Quick Ratio for the trailling 12 Months

IMRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 24.49 % 23.74 % 23.91 % 7.7 % 2.9 %
Y / Y Cash & cash equivalent TTM Growth 198.79 % 135.69 % 92.11 % 21.92 % -52.53 %
Quick Ratio TTM 13.95 13.9 13.45 11.56 5.81
Total Ranking TTM # 3174 # 2361 # 2471 # 2659 # 2583
Seq. Current Liabilities TTM Growth 3.22 % -0.62 % 10.31 % 10.02 % 2.6 %
Seq. Cash & cash equivalent TTM Growth 3.58 % 2.74 % 28.38 % 118.71 % -18.3 %

Quick ratio ranking by company, industry and sector >> Back to IMRX Financial Strength Comparisons >> Go to Compare IMRX Quick Ratio to its Competitors

On the trailing twelve months basis IMRX Cash & cash equivalent soared by 58.34 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Immuneering's Quick Ratio to 13.95, Quick Ratio remained below IMRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 412 other companies have achieved higher Quick Ratio than Immuneering. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2361 to 3174.

Explain Quick Ratio?
How much Cash & cash equivalents IMRX´s has?
What are IMRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 413
Healthcare Sector # 829
Within the Market # 3174


trailing twelve months Quick Ratio Statistics
High Average Low
30.72 15.79 5.52
(Jun 30 2022)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions
Coya Therapeutics Inc   12.29 $ 43.181  Millions$ 3.512  Millions
Bridgebio Oncology Therapeutics Inc   12.28 $ 634.167  Millions$ 51.634  Millions
Ocular Therapeutix Inc   12.17 $ 598.641  Millions$ 49.174  Millions
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions

Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.